Fig 2: Effects of Nogo-66 on the expression levels and enzymatic activity of proteins involved in the Aß pathway in the hippocampus of Sprague-Dawley rats. (A) Schematic diagram of treatment of rats with Nogo-66. Nogo-66 induced (B) Aß40 and (C) Aß42 production in a dose-dependent manner in the brains of rats. Data are presented as the mean ± SD (n=6). *P<0.05, **P<0.01 vs. control. (D) Western blotting results showing the protein expression levels of APP, C99, sAPPa and BACE1 in the hippocampus. (E-H) Semi-quantification of western blotting. (I) Western blot analysis of the expression levels of ROCK2, p-CRMP2 and CRMP2 in the hippocampus. Semi-quantification of (J) p-CRMP2 and (K) ROCK2 protein. Equal protein loading was confirmed using GAPDH. (L) ADAM10 and (M) BACE1 activity in the hippocampus of Sprague-Dawley rats was measured. Data are presented as the mean OD values ± SD of triplicate samples (n=3). *P<0.05, **P<0.01, ***P<0.001 vs. control. APP, amyloid precursor protein; sAPPa, secreted APP-a; BACE1, ß-secretase 1; Aß, ß-amyloid protein; CRMP2, collapsin response mediator protein-2; p-, phosphorylated; ROCK2, Rho-associated coiled-coil containing kinase 2; OD, optical density.